https://www.benitec.com/ https://www.benitec.com/about-us https://www.benitec.com/our-science/gene-silencing https://www.benitec.com/our-science/intellectual-property https://www.benitec.com/our-science/partnering https://www.benitec.com/our-programs/areas-of-research https://www.benitec.com/our-programs/pipeline https://www.benitec.com/our-programs/presentations-and-publications https://www.benitec.com/our-programs/clinical-trials https://www.benitec.com/for-investors https://www.benitec.com/for-investors/news-events/press-releases https://www.benitec.com/for-investors/news-events/ir-calendar https://www.benitec.com/for-investors/news-events/media-coverage https://www.benitec.com/for-investors/news-events/email-alerts https://www.benitec.com/for-investors/company-info https://www.benitec.com/for-investors/company-info/management-team https://www.benitec.com/for-investors/company-info/presentations https://www.benitec.com/for-investors/company-info/contacts https://www.benitec.com/for-investors/company-info/faq https://www.benitec.com/for-investors/financial-info https://www.benitec.com/for-investors/financial-info/financial-results https://www.benitec.com/for-investors/financial-info/annual-reports https://www.benitec.com/for-investors/stock-data/quote-chart https://www.benitec.com/for-investors/stock-data/historical-data https://www.benitec.com/for-investors/stock-data/analyst-coverage https://www.benitec.com/for-investors/sec-filings/all-sec-filings https://www.benitec.com/for-investors/sec-filings/annual-reports https://www.benitec.com/for-investors/sec-filings/quarterly-reports https://www.benitec.com/for-investors/sec-filings/section-16-filings https://www.benitec.com/for-investors/governance https://www.benitec.com/for-investors/governance/board-of-directors https://www.benitec.com/for-investors/governance/board-committees https://www.benitec.com/for-investors/governance/governance-documents https://www.benitec.com/for-investors/governance/board-diversity-matrix https://www.benitec.com/contact-us https://www.benitec.com/for-investors/news-events/press-releases/detail/145/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd 2026-03-10T07:00:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/144/benitec-biopharma-announces-positive-interim-phase-1b2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-scientific-conference 2026-03-09T07:00:03-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/143/benitec-biopharma-announces-acceptance-of-late--breaking-abstract-for-the-bb-301-phase-1b2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-scientific-conference 2026-02-23T07:00:03-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update 2026-02-12T08:52:31-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response 2026-01-11T08:00:01-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/140/benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational-update 2025-11-14T17:00:02-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering 2025-11-06T00:19:47-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/138/benitec-biopharma-inc-announces-proposed-public-offering 2025-11-05T16:43:01-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/137/benitec-biopharma-provides-positive-interim-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-and-receives-fda-fast-track-designation-for-bb-301 2025-11-03T07:10:01-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/136/benitec-biopharma-announces-appointment-of-sharon-mates-ph-d-to-its-board-of-directors 2025-11-03T07:00:41-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/135/benitec-biopharma-to-provide-phase-1b2a-clinical-study-update-for-bb-301-in-oculopharyngeal-muscular-dystrophy 2025-11-02T19:00:02-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/134/benitec-biopharma-releases-full-year-2025-financial-results-and-provides-operational-update 2025-09-22T16:05:07-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/133/benitec-biopharma-provides-operational-updates 2025-07-09T08:00:18-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/132/benitec-biopharma-releases-third-quarter-2025-financial-results 2025-05-14T07:00:05-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/131/benitec-biopharma-inc-announces-pricing-of-30-million-common-stock-offering 2025-03-25T08:00:08-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/130/benitec-biopharma-reports-positive-interim-clinical-results-for-three-subjects-treated-with-bb-301-in-phase-1b2a-study-to-be-presented-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference 2025-03-19T07:00:11-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/129/benitec-biopharma-to-participate-in-upcoming-conferences-in-march 2025-02-26T07:00:01-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/128/benitec-biopharma-releases-second-quarter-2025-financial-results-and-provides-operational-update 2025-02-14T08:10:02-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/127/benitec-biopharma-announces-acceptance-of-late--breaking-oral-abstract-for-the-bb-301-phase-1b2a-clinical-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference 2025-02-14T08:00:04-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/126/benitec-biopharma-to-participate-in-upcoming-conferences-in-january-and-february 2025-01-27T08:00:09-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/125/benitec-biopharma-to-participate-in-upcoming-investor-conferences-in-december 2024-11-26T07:00:16-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/124/benitec-biopharma-releases-first-quarter-2025-financial-results-and-provides-operational-update 2024-11-14T16:30:02-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/123/benitec-biopharma-ceo-to-participate-in-the-guggenheim-securities-healthcare-conference 2024-11-04T08:00:08-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/122/benitec-biopharma-announces-updated-investor-webcast-information 2024-10-14T06:00:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/121/benitec-biopharma-reports-positive-data-from-two-subjects-treated-with-low-dose-bb-301-in-phase-1b2a-study-presented-at-29th-annual-congress-of-the-world-muscle-society 2024-10-12T06:30:04-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/120/benitec-biopharma-releases-full-year-2024-financial-results-and-provides-operational-update 2024-09-26T16:30:22-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/119/benitec-biopharma-announces-late-breaking-oral-abstract-presentation-on-bb-301-phase-1b2a-clinical-study-at-the-29th-annual-congress-of-the-world-muscle-society 2024-09-18T08:00:06-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/118/benitec-biopharma-ceo-to-participate-in-opmd-awareness-day-webinar 2024-09-17T08:00:06-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/117/benitec-biopharma-reports-continued-durable-improvements-in-the-radiographic-assessments-of-swallowing-efficiency-and-the-subject-reported-outcome-instrument-at-the-180-day-timepoint-for-first-opmd-subject-treated-with-low-dose-bb-301-in-phase-1b2a-study 2024-07-15T06:00:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/116/benitec-biopharma-announces-appointment-of-kishen-mehta-to-its-board-of-directors 2024-07-01T07:00:03-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/115/benitec-biopharma-releases-third-quarter-2024-financial-results-and-provides-operational-update 2024-05-13T08:15:19-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/114/benitec-biopharma-to-participate-in-the-citizens-jmp-life-science-conference 2024-05-01T08:00:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/113/benitec-biopharma-reports-positive-interim-clinical-trial-data-for-first-opmd-subject-treated-with-bb-301-in-phase-1b2a-study 2024-04-18T07:30:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/112/benitec-biopharma-announces-oversubscribed-private-placement-financing-of-40-0-million 2024-04-18T07:00:01-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/111/benitec-biopharma-to-host-virtual-rd-day-to-discuss-bb-301-clinical-program-in-oculopharyngeal-muscular-dystrophy-on-april-18-2024 2024-04-09T08:00:03-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/110/benitec-biopharma-releases-second-quarter-2024-financial-results-and-provides-operational-update 2024-02-13T08:00:06-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/109/benitec-biopharma-announces-first-subject-dosed-in-phase-1b2a-clinical-trial-for-gene-therapy-candidate-bb-301-for-the-treatment-of-oculopharyngeal-muscular-dystrophy 2023-11-30T07:00:06-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/108/benitec-biopharma-to-participate-in-a-fireside-chat-at-the-35th-annual-piper-sandler-healthcare-conference 2023-11-17T08:00:01-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/107/benitec-biopharma-releases-first-quarter-2024-financial-results-and-provides-operational-update 2023-11-13T08:00:11-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/106/benitec-biopharma-releases-full-year-2023-financial-results-and-provides-operational-update 2023-09-21T08:00:07-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/105/benitec-biopharma-inc-announces-closing-of-30-million-underwritten-public-offering 2023-08-11T13:00:13-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/104/benitec-biopharma-inc-announces-pricing-of-30-million-underwritten-public-offering 2023-08-08T22:30:14-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/103/benitec-biopharma-announces-1-for-17-reverse-stock-split-effective-july-26-2023 2023-07-25T13:00:01-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/102/benitec-biopharma-receives-fda-clearance-of-the-ind-for-bb-301-for-the-treatment-of-oculopharyngeal-muscular-dystrophy 2023-06-26T08:00:07-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/101/benitec-biopharma-releases-third-quarter-2023-financial-results-and-provides-operational-update 2023-05-15T08:00:08-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/100/benitec-biopharma-to-present-at-the-opmd-international-conference 2023-05-08T08:05:01-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/99/benitec-biopharma-to-present-at-the-jmp-securities-life-sciences-conference 2023-05-08T08:00:08-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/98/benitec-biopharma-releases-second-quarter-2023-financial-results-and-provides-operational-update 2023-02-13T08:00:07-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/97/benitec-biopharma-enrolls-first-opmd-subject-into-the-clinical-development-program 2023-01-23T09:48:02-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/96/benitec-biopharma-releases-first-quarter-2023-financial-results-and-provides-operational-update 2022-11-10T08:00:17-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/95/benitec-biopharma-inc-announces-closing-of-18-million-underwritten-public-offering 2022-09-16T08:42:37-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/94/benitec-biopharma-inc-announces-pricing-of-18-million-underwritten-public-offering 2022-09-12T22:06:01-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/93/benitec-biopharma-releases-full-year-2022-financial-results-and-provides-operational-update 2022-09-02T08:00:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/92/benitec-biopharma-releases-q3-2022-financial-results 2022-05-16T08:15:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/91/benitec-biopharma-discloses-q2-2022-financial-results 2022-02-14T08:00:22-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/90/benitec-biopharma-discloses-q1-2022-financial-results 2021-11-15T08:00:21-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/89/benitec-biopharma-provides-operational-update-and-releases-its-2021-fiscal-year-end-financial-results 2021-12-10T11:44:06-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/88/benitec-biopharma-to-present-at-h-c-wainwrights-23rd-annual-global-investment-conference 2021-09-20T10:04:51-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/87/benitec-biopharma-provides-overview-of-the-bb-301-phase-1b2a-clinical-trial-design-for-2022 2021-09-08T08:10:05-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/86/benitec-biopharma-provides-positive-updates-on-the-bb-301-pilot-dosing-study-in-large-animals 2021-09-08T08:05:06-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/85/benitec-biopharma-provides-positive-regulatory-updates-for-the-bb-301-development-program-bb-301-phase-1b2a-clinical-trial-to-begin-in-2022 2021-09-08T08:01:05-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/84/benitec-biopharma-increases-previously-announced-bought-deal-offering-of-common-stock-to-12-9-million 2021-04-27T21:55:34-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/83/benitec-biopharma-announces-7-5-million-bought-deal-offering-of-common-stock 2021-04-27T16:44:39-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/82/benitec-biopharma-announces-successful-results-from-the-interim-analysis-of-the-bb-301-pilot-dosing-study 2021-02-24T08:29:37-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/81/benitec-biopharma-announces-2020-annual-stockholder-meeting 2020-12-07T14:33:31-05:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/80/benitec-biopharma-announces-closing-of-11-5-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2020-10-06T16:05:02-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/79/benitec-biopharma-announces-pricing-of-10-0-million-public-offering 2020-10-02T09:05:03-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/78/benitec-biopharma-provides-operational-update-and-releases-its-2020-fiscal-year-end-financial-results 2020-10-09T10:18:13-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/5/benitec-biopharma-to-present-at-h-c-wainwrights-22nd-annual-global-investment-conference 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/6/benitec-biopharma-provides-update-on-bb-301-tissue-transduction-study 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/7/benitec-biopharma-announces-the-completion-of-redomiciliation-to-the-united-states 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/8/benitec-biopharma-appoints-edward-smith-to-the-board-of-directors 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/9/benitec-announces-supreme-court-of-queensland-approval-for-redomicile 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/10/benitec-announces-results-of-scheme-meeting 2020-09-01T12:49:41-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/11/appendix-4c-quarterly-cash-flow-report 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/12/asxnasdaq-announcement-re-domiciliation-to-the-united-states 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/13/appendix-4c-quarterly-cash-flow-report 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/14/benitec-biopharma-limited-announces-us2-25-million-registered-direct-offering 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/15/benitec-biopharma-to-present-at-ladenburg-thalmann-2019-healthcare-conference 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/16/benitec-biopharma-provides-update-on-bb-301-oculopharyngeal-muscular-dystrophy-opmd-program 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/17/asxnasdaq-announcement-appendix-4c-quarterly-cash-flow-report 2020-09-01T12:49:42-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/18/update-on-oculopharyngeal-muscular-dystrophy-program 2020-09-01T12:49:43-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/19/benitec-provides-update-on-bb-401-cancer-treatment-program 2020-09-01T12:49:43-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/20/benitec-biopharma-announces-the-appointment-of-gregory-r-reyes-m-d-ph-d-as-senior-scientific-advisor 2020-09-01T12:49:43-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/21/benitec-announces-global-licensing-agreement-for-bb-301-for-treatment-of-oculopharyngeal-muscular-dystrophy-and-broad-platform-collaboration-with-axovant 2020-09-01T12:49:43-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/22/benitec-biopharma-reports-financial-results-for-the-2018-fiscal-third-quarter-and-provides-operational-update 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/23/benitec-to-present-opmd-data-at-the-american-society-of-gene-and-cell-therapy-meeting 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/24/benitec-to-host-investor-webinar-on-the-companys-oculopharyngeal-muscular-dystrophy-opmd-program 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/25/asxnasdaq-announcement 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/26/benitec-biopharma-launches-its-phase-2-oncology-study-in-australia 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/27/benitec-biopharma-reports-financial-results-for-the-2018-fiscal-second-quarter-and-provides-operational-update 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/28/federal-rd-tax-credit-received 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/29/benitec-receives-u-s-orphan-drug-designation-for-bb-301-its-ddrnai-therapeutic-for-the-treatment-of-oculopharyngeal-muscular-dystrophy 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/30/benitec-biopharma-provides-update-on-opmd-orphan-disease-program 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/31/u-s-patent-granted-for-benitec-hepatitis-b-program 2020-09-01T12:49:44-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/32/benitec-biopharma-advances-opmd-orphan-disease-program 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/33/key-pre-clinical-data-on-oculopharyngeal-muscular-dystrophy-opmd-published-in-nature-communications 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/34/benitec-biopharma-completes-second-tranche-placement-to-nant-capital-to-raise-a5-45-million 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/35/benitec-biopharma-to-present-expanded-data-set-from-pivotal-data-in-hepatitis-b-virus-hbv-in-vivo-model-at-international-liver-meeting-in-shanghai-china 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/36/benitec-biopharma-makes-significant-progress-in-ocular-program 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/37/benitec-initiates-development-work-on-head-and-neck-cancer-programs-after-executing-collaboration-agreement-with-nant-capital 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/press-releases/detail/38/benitec-receives-orphan-drug-designation-in-the-european-union-for-bb-301-a-ddrnai-therapeutic-in-development-for-the-treatment-of-oculopharyngeal-muscular-dystrophy 2020-09-01T12:49:45-04:00 https://www.benitec.com/for-investors/news-events/ir-calendar/detail/20251201-2025-annual-meeting-of-stockholders 2025-10-14T17:04:54-04:00 https://www.benitec.com/for-investors/news-events/ir-calendar/detail/20251103-interim-bb-301-phase-1b2a-clinical-study-update 2025-11-03T03:33:07-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001193125-26-117604/d226768d10ka.htm 2026-03-20T16:04:44-04:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001193125-26-047742/bntc-20260212.htm 2026-02-12T08:10:50-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001193125-26-047737/bntc-20251231.htm 2026-02-12T08:09:17-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001193125-26-044984/d10746d424b3.htm 2026-02-11T06:01:12-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/9999999995-26-000516/primary_doc.html 2026-02-11T06:06:57-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001193125-26-031753/d10746ds3.htm 2026-01-30T16:03:25-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0000038777-26-000024/primary_doc.html 2026-01-29T11:34:34-05:00 https://www.benitec.com/for-investors/sec-filings/all-sec-filings/content/0001012975-26-000082/form4.html 2026-01-26T16:10:38-05:00 https://www.benitec.com/privacy-policy https://www.benitec.com/disclaimer https://www.benitec.com/sitemap https://www.benitec.com/accessibility-statement